Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
April 7th, 2023
6.2K views
This protocol provides methods for generating 3D engineered cardiac and skeletal muscle tissues and describes their use in preclinical drug screening modalities. The described methods utilize a magnetic sensing system to facilitate the simultaneous assessment of 24 tissues in parallel.
Overview
This protocol outlines the generation of 3D engineered cardiac and skeletal muscle tissues, utilizing a magnetic sensing system for drug screening. The methods allow for the simultaneous assessment of 24 tissues, enhancing throughput in preclinical studies.
Key Study Components
Area of Science
- Cardiac and skeletal muscle engineering
- Preclinical drug screening
- Tissue modeling
Background
- 3D engineered muscle tissues provide a relevant in vitro model for studying muscle diseases.
- Magnetic sensing technology enables high-throughput contractility measurements.
- Improved consistency in tissue fabrication is crucial for reliable experimental outcomes.
- Incorporation of motor neurons aims to create a neuromuscular junction model.
Purpose of Study
- To develop a method for generating consistent 3D muscle tissues.
- To facilitate drug discovery and disease modeling using human muscle tissues.
- To enhance the throughput of contractility assessments in vitro.
Methods Used
- Preparation of casting plates and thrombin solutions for tissue formation.
- Cell dissociation and counting to ensure proper cell density.
- Casting of muscle tissues using fibrinogen and thrombin solutions.
- Incubation and transfer of tissues to differentiation media.
Main Results
- Successful generation of 3D engineered muscle tissues with consistent contractility.
- Maximal compaction of tissues observed by day 21.
- Immunohistochemical analysis confirmed the presence of muscle-specific proteins.
- High-throughput assessment of contractility across multiple tissues was achieved.
Conclusions
- The developed protocol allows for efficient generation and assessment of muscle tissues.
- This method can significantly aid in drug discovery and modeling muscle diseases.
- Future work will focus on integrating motor neurons into the constructs.
Frequently Asked Questions
What is the significance of using 3D engineered muscle tissues?
3D engineered muscle tissues provide a more physiologically relevant model for studying muscle function and disease compared to traditional 2D cultures.
How does the magnetic sensing system work?
The magnetic sensing system measures the contractility of muscle tissues by detecting changes in magnetic fields as the tissues contract.
What are the advantages of this high-throughput method?
This method allows simultaneous assessment of multiple tissues, increasing efficiency and reducing the time needed for drug screening.
Can this method be applied to other types of tissues?
While this protocol focuses on muscle tissues, the principles may be adapted for other tissue types in future studies.
What challenges are associated with tissue fabrication?
Challenges include ensuring tissue attachment, avoiding air bubbles, and achieving uniform tissue deposition.
What future directions does this research aim to explore?
Future research will explore integrating motor neurons to create a neuromuscular junction model and further applications in gene therapy.
Executive Industry Relevance
Scalable 3D engineered muscle tissue platforms address a critical gap in preclinical drug testing by enabling reproducible, quantitative assessment of contractile function in both healthy and disease models. This technology enhances predictive confidence for cardiotoxicity and myotoxicity, supporting earlier de-risking and more informed portfolio decisions. Integration of high-throughput, label-free contractility assays positions these models as pivotal tools for translational continuity from discovery through preclinical validation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses in disease-relevant muscle systems.
- Supports mechanistic de-risking by quantifying contractile responses to candidate compounds.
- Facilitates functional target validation through direct measurement of muscle force and kinetics.
Screening & Assay Development
- Provides standardized, reproducible 3D muscle constructs for compound screening workflows.
- Delivers quantitative, high-throughput contractility readouts across 24 tissues simultaneously.
- Reduces assay variability and supports scalable screening for cardiotoxic and myotoxic liabilities.
Translational & Preclinical Research
- Aligns in vitro contractility metrics with translational biomarkers for cardiac and skeletal muscle safety.
- Enables longitudinal analysis of acute and chronic drug effects in engineered tissues.
- Supports risk-adjusted advancement by modeling clinically relevant toxicities, such as those seen with BMS-986094.
Pipeline & Workflow Integration
This platform bridges early discovery, lead identification, and preclinical safety assessment by providing a unified, scalable system for functional muscle evaluation.
- Discovery Biology: Supports hypothesis testing and pathway clarification in engineered muscle models.
- Screening: Delivers reproducible, quantitative contractility data for compound triage.
- Analytics: Enables dose-response and longitudinal measurement of force and kinetics.
- Translational Research: Facilitates alignment with clinical safety endpoints for muscle function.
- Enterprise Reuse: Offers a reusable, automation-friendly platform adaptable to diverse cell sources and disease models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence for muscle-related drug safety and efficacy.
- Operational Value: Standardizes tissue fabrication and measurement, reducing failure rates and manual intervention.
- Strategic Value: Improves go/no-go decisions by providing early, quantitative safety data.
- Portfolio Impact: Enables risk-adjusted prioritization and reduces late-stage attrition due to unforeseen muscle toxicities.
Implementation Considerations
- Requires expertise in 3D tissue culture and contractility assay operation.
- Needs access to magnetic sensing hardware and compatible 24-well casting plates.
- Demands cross-team standardization for data analysis and tissue fabrication protocols.
- Adaptable to various cell sources, including iPSC-derived and primary myoblasts.
- Limitations include potential for tissue detachment, air bubbles, and structural inconsistencies if protocols are not rigorously followed.
Biopharma FAQs
Why does null hypothesis testing matter for contractility assays?
Null hypothesis testing in contractility assays enables objective evaluation of whether a compound induces statistically significant changes in muscle force, supporting robust target validation and early de-risking of candidate drugs.
How does independent variable isolation fit scalable 3D muscle screening?
Isolating variables such as compound concentration or dosing regimen in the 24-well platform allows precise attribution of contractile changes to specific interventions, streamlining discovery-stage decision making.
What do quantitative force measurements enable in preclinical workflows?
Quantitative force and kinetics data provide actionable endpoints for dose-response analysis, enabling teams to compare compound effects and prioritize leads based on functional outcomes.
Why are replication requirements critical for cross-functional teams?
Replication across multiple engineered tissues ensures reproducibility and reliability of contractility data, facilitating collaboration between discovery, safety, and translational research groups.
Which statistical analyses are required before contractility data implementation?
Statistical analyses such as dose-response modeling and significance testing are essential to validate contractility outputs, ensuring that only robust, reproducible findings inform pipeline advancement.
